Avoro Capital Advisors Portfolio
13F Holdings & Position Changes — Last filed Aug 14, 2026
13F Holdings & Position Changes — Last filed Aug 14, 2026
Biotech specialist fund (formerly Venbio Select Advisor) that takes concentrated positions in clinical and commercial-stage companies. Aghazadeh, a biochemist, is known for activist-style engagement and has served on multiple biotech boards to drive value creation.
Avoro Capital Advisors is a $6B biotech-focused hedge fund managed by Behzad Aghazadeh, PhD. As of their latest 13F filing (Q2 2026), the fund holds 25 positions worth $11.1B. This quarter they initiated 2 new positions and exited 53. Their largest holding is UTHR ($1.5B).
Avoro initiated 2 new positions and increased 11 this quarter. Portfolio grew +9.6% to $11.1B. 436 upcoming catalysts across holdings.
Portfolio Value (13F)
$11.1B
Holdings
25
Top 10 Concentration
79.8%
QoQ Change
+9.6%
Turnover
1.0%
Portfolio Value Trend
Be first to know when Avoro Capital Advisors files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics Corporation | Increased↑3Q | $1.5B | 13.57% | 6.0% | |
| 2 | ASND | Ascendis Pharma A/S | Increased | $1.4B | 12.29% | 3.6% | |
| 3 | KRYS | Krystal Biotech Inc. | $1.1B | 9.68% | 17.7% | ||
| 4 | MDGL | Madrigal Pharmaceuticals Inc. | Held↑2Q | $984.4M | 8.88% | 10.3% | |
| 5 | ARGX | argenx SE | $927.8M | 8.37% | 3.3% | ||
| 6 | ARWR | Arrowhead Pharmaceuticals Inc. | Increased↑2Q | $925.6M | 8.35% | 9.1% | |
| 7 | KYMR | Kymera Therapeutics Inc. | $857.1M | 7.73% | 16.1% | ||
| 8 | RVMD | Revolution Medicines Inc. | Decreased | $430.2M | 3.88% | 4.8% | |
| 9 | CYTK | Cytokinetics Incorporated | Increased↑2Q | $425.9M | 3.84% | 17.9% | |
| 10 | CELC | Celcuity Inc. | Increased↑3Q | $355.7M | 3.21% | 32.3% |
Share changes reflect active decisions. Value changes include price moves.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
See all 25 holdings (you're viewing the top 10), plus 14 quarters of position history.
No charge for 14 days · Cancel anytime
Avoro Capital Advisors held 25 biotech stocks in their 13F portfolio this quarter. Their top positions include UTHR, ASND, KRYS, MDGL, ARGX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Avoro Capital Advisors's tracked biotech portfolio is worth $11.1B across 25 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
Avoro Capital Advisors initiated 2 new positions this quarter, including COAG, SNSE. They also increased 11 existing positions.
Avoro Capital Advisors fully exited 53 positions this quarter, including RNA, PCVX, INCY, MNMD, ORKA and 48 more. They also trimmed 3 existing positions.
Biotech specialist fund (formerly Venbio Select Advisor) that takes concentrated positions in clinical and commercial-stage companies. Aghazadeh, a biochemist, is known for activist-style engagement and has served on multiple biotech boards to drive value creation.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial